Focused on high-risk heart attack and stroke patients, the new recommendation are for aggressive drug therapy to lower cholesterol.» Read More
NEW YORK, Dec 3- A U.S. federal judge has awarded AstraZeneca Plc $76 million in damages from generic drug manufacturer Apotex for infringing upon patents for AstraZeneca's blockbuster heartburn drug, Prilosec, between 2003 and 2007..
An "import alert" results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, according to the FDA website.
*Bid at 27 percent premium to Algeta share price at Monday's close. *Algeta shares rise above Bayer offer price in early trade. OSLO/ LONDON, Nov 26- Bayer has offered to pay $2.4 billion for Norway's Algeta, its partner for a new prostate cancer treatment, at a 27 percent premium to the stock's last close, Algeta said on Tuesday.
*Bid at 27 percent premium to Algeta share price at Monday's close. *Algeta shares rise above Bayer offer price in early trade. OSLO/ LONDON, Nov 26- Bayer has offered to pay $2.4 billion for Norway's Algeta, its partner for a new prostrate cancer treatment, a 27 percent premium to the stock's last close, Algeta said on Tuesday.
LONDON, Nov 22- European regulators have recommended approval of a new drug from Gilead Sciences to treat hepatitis C and an HIV medicine from GlaxoSmithKline, both of which are expected to be major sellers.
Dallas, Nov 18- Top cardiologists who devised new U.S. guidelines for reducing risk of heart disease strenuously defended their risk-calculation tool from criticism that it greatly overestimates health risks and the need to be treated with cholesterol lowering statin drugs.
But use of Merck& Co's widely prescribed Zetia, which is not a statin, and Vytorin, a related drug, will likely not be badly hurt anytime soon, analysts said, because doctors will need time to understand and accept the new guidelines. The Merck drugs have combined annual sales of more than $4 billion, or 10 percent of overall company revenue.
Pfizer Inc, Amgen Inc and a partnership of Regeneron Inc and French drugmaker Sanofi SA are racing to develop the new family of medicines called PCSK9 inhibitors. "I read the new guidelines as a negative for any drugs that aren't statins, including PCSK9 inhibitors," said Jon LeCroy, an analyst with MKM Partners.
LONDON, Nov 11- Cardiologists and shareholders in GlaxoSmithKline are about to learn if a big gamble on a new kind of heart medicine has paid off, with modest expectations creating a potentially big share price boost if the news is good.
LONDON, Oct 31- AstraZeneca is being investigated by U.S. authorities over a major clinical trial that was used to win marketing approval for its new heart drug Brilinta, casting fresh doubts over the medicine. AstraZeneca plans to cooperate with the DOJ and Chief Executive Pascal Soriot said he was "very confident" in the findings of the clinical trial.
LONDON, Oct 31- AstraZeneca promoted Marc Dunoyer to be its new chief financial officer on Thursday, plugging a gap in the British drugmaker's top management team as it grapples with falling sales and profits.
*Experimental drug mimics GLP-1 and GIP hormones. LONDON, Oct 30- An experimental drug that mimics the effects of two naturally occurring hormones appears to work significantly better than existing single-hormone medicines against diabetes and obesity, scientists said on Wednesday.
Oct 24- Rigel Pharmaceuticals Inc said it would stop the development of its drug to treat skin lesions in patients with discoid lupus, a chronic skin disease, after the treatment failed a mid-stage trial. British drugmaker AstraZeneca stopped developing Rigel's rheumatoid arthritis treatment, fostamatinib, in June, which it licensed from Rigel in 2010..
*China sales slump 61 percent as doctors shun GSK products. LONDON, Oct 23- GlaxoSmithKline's drug sales in China slumped 61 percent in the third quarter, hit by a bribery scandal that has damaged its ability to market products in the country and pushed some sales into the hands of rivals.
NEW YORK/ PARIS, Oct 16- A new type of cholesterol drug from Regeneron Pharmaceuticals Inc and Sanofi SA, when used by itself, cut levels of "bad" LDL cholesterol almost in half in the first of a dozen late-stage trials of the medicine.
LONDON, Oct 16- Mark Reilly, GlaxoSmithKline's former head of operations in China, is helping anti-corruption officials in the country who are investigating allegations of extensive bribery by the drugmaker. One person familiar with the situation said Reilly had been requested to remain in China while the investigations proceeded and was happy to do so.
PARIS, Oct 14- Sanofi, trying to squeeze more out of R&D spending like other big drugmakers, is finding its home market France a difficult place to cut costs because of complex labour laws, union opposition and a government eager to protect jobs.
*Sees 2013 revenue near midpoint of $19.5- $20.5 bln estimate. JERUSALEM, Oct 10- Teva Pharmaceutical Industries will cut about 5,000 jobs, 10 percent of its workforce, accelerating a cost-cutting plan as it prepares for lower-priced competition for its best-selling drug.
LONDON, Oct 2- A U.S. court has lifted a temporary block stopping South Korea's Hanmi Pharmaceutical from launching a close relative of AstraZeneca's Nexium stomach-acid drug in the United States.
LONDON, Sept 30- Fixing ailing drugmaker AstraZeneca remains a work in progress for Chief Executive Pascal Soriot, with sales and profits still heading firmly downhill after his first year in the job.